Security key
107924102
BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT)
CUSIP: 107924102
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 57,897,060
- Total 13F value
- $724,704,890
- Share change
- +1,058,225
- SEC-reported price per share
- $12.52
- Number of holders
- 52
- Value change
- +$13,675,814
- Number of buys
- 25
- Number of sells
- 15
- Shares outstanding
- 80,458,364
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q4 2025
Institutions
52
Top holders
10
BBOT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
BridgeBio Oncology Therapeutics, Inc. SEC filings
BridgeBio Oncology Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 107924102
Recent filing periods:
Ownership snapshot
Top reported holders of BBOT - BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Helix Holdings II LLC
Disclosed value leader
Cormorant Asset Managemen...
Comparable rows
15/15
Latest evidence
10 Oct 2025
13D/G
3/4/5
13F
Lead comparable stake: 23%
13D/G row: Helix Holdings II LLC
Showing 1-6 of 15 holder rows.
Quick read
Helix Holdings II LLC leads the comparable SEC ownership view at 23%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Helix Holdings II LLC
23%
BridgeBio Pharma LLC
18%
BlackRock Portfolio Management LLC
7.9%
James E. Flynn
6.2%
BC Global Opportunities IX LP
5.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Helix Holdings II LLC |
13D/G
3/4/5
Bihua Chen · Director, 10%+ Owner
|
23%
|
—
17,878,594 shares
|
$0 | 11 Aug 2025 |
| BridgeBio Pharma LLC |
3/4/5
13D/G
10%+ Owner
|
18%
from 13D/G
|
$156,363,757
14,589,846 shares
|
— | 10 Oct 2025 |
| BlackRock Portfolio Management LLC |
13D/G
|
7.9%
|
—
1,498,865 shares
|
$0 | 31 Mar 2025 |
| James E. Flynn |
13D/G
Deerfield Management Company, L.P.
|
6.2%
|
—
4,885,446 shares
|
$0 | 11 Aug 2025 |
| BC Global Opportunities IX LP |
13D/G
|
5.5%
|
$42,740,663
4,365,747 shares
|
$0 | 04 Sep 2025 |
| Sculptor Capital LP |
13D/G
|
5.1%
|
$10,419,544
967,460 shares
|
$0 | 17 Jul 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
52
Shares
57,897,060
Rows available
52
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
41
Q4 2025 holders
52
Holder diff
11
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend